| Literature DB >> 25025061 |
Janet Piloto Ferrer1, Renata Cozzi2, Tommaso Cornetta2, Pasquale Stano2, Mario Fiore3, Francesca Degrassi3, Rosella De Salvia3, Antonia Remigio1, Marbelis Francisco1, Olga Quiñones1, Dayana Valdivia1, Maria L González1, Carlos Pérez4, Angel Sánchez-Lamar5.
Abstract
Xanthium strumarium L. is a member of the Asteraceae commonly used in Cuba, mainly as diuretic. Some toxic properties of this plant have also been reported and, to date, very little is known about its genotoxic properties. The present work aims was to evaluate the potential cytotoxic and genotoxic risk of whole extract from Xanthium strumarium L. whole extract of aerial parts. No positive response was observed in a battery of four Salmonella typhimurium strains, when exposed to concentrations up to 5 mg/plate, with and without mammalian metabolic activation (liver microsomal S9 fraction from Wistar rats). In CHO cells, high concentrations (25-100 μg/mL) revealed significant reduction in cell viability. Results from sister chromatid exchanges, chromosome aberrations, and comet assay showed that X. strumarium extract is genotoxic at the highest concentration used, when clear cytotoxic effects were also observed. On the contrary, no increase in micronuclei frequency in bone marrow cells was observed when the extract was orally administered to mice (100, 500, and 2000 mg/Kg doses). The data presented here constitute the most complete study on the genotoxic potential of X. strumarium L. and show that the extract can induce in vitro DNA damage at cytotoxic concentrations.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25025061 PMCID: PMC4082875 DOI: 10.1155/2014/575197
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Mutagenicity testing of Xanthium strumarium extract in the Salmonella/microsome assay (TA 1535 and TA 1537).
| Concentration |
TA 1535 |
TA 1537 | ||
|---|---|---|---|---|
| −S9 | +S9 | −S9 | +S9 | |
| 0a | 26.00 ± 8.54 | 10.3 ± 2.52 | 9.67 ± 2.89 | 8.00 ± 0.0 |
| 50 | 21.67 ± 4.04 | 9.00 ± 1.73 | 9.33 ± 0.58 | 7.33 ± 2.08 |
| 150 | 23.67 ± 2.08 | 8.67 ± 4.16 | 8.00 ± 1.00 | 6.00 ± 2.00 |
| 500 | 28.33 ± 9.07 | 11.33 ± 2.52 | 14.00 ± 3.46 | 8.33 ± 3.21 |
| 1500 | 32.67 ± 2.08 | 10.33 ± 6.11 | 12.33 ± 3.08 | 6.67 ± 2.31 |
| 5000 | 28.67 ± 1.53 | 5.67 ± 2.52 | 16.3 ± 4.93 | 7.33 ± 4.04 |
| NaA1.5b | 405.3 ± 70.5∗∗ | |||
| CP 500b | 228.3 ± 36.2∗∗ | |||
| 9AA 100b | 460.0 ± 50.0∗∗ | |||
| 2AF 20b | 580.0 ± 34.6∗∗ | |||
+S9: with liver microsomal S9 fraction; −S9: without liver microsomal S9 fraction.
aNegative control, dimethyl sulfoxide (DMSO).
bPositive controls. NaA: sodium azide; CP: cyclophosphamide; 9AA: 9-aminoacridine; 2AF: 2-aminofluorene.
∗∗ P < 0.01 (Student's t-test).
Mutagenicity testing of Xanthium strumarium extract in the Salmonella/microsome assay (TA 100 and TA 98).
| Concentration |
TA 100 |
TA 98 | ||
|---|---|---|---|---|
| −S9 | +S9 | −S9 | +S9 | |
| 0a | 58.33 ± 16.56 | 62.60 ± 15.1 | 25.67 ± 3.79 | 38.33 ± 2.52 |
| 50 | 54.33 ± 5.13 | 64.10 ± 10.5 | 26.00 ± 4.36 | 38.67 ± 11.85 |
| 150 | 45.33 ± 4.73 | 60.04 ± 13.7 | 28.67 ± 7.64 | 45.67 ± 8.33 |
| 500 | 44.00 ± 2.00 | 60.33 ± 5.77 | 22.00 ± 5.29 | 35.67 ± 20.11 |
| 1500 | 46.67 ± 2.52 | 70.70 ± 7.37 | 26.00 ± 4.36 | 40.67 ± 8.62 |
| 5000 | 51.67 ± 3.21 | 67.31 ± 2.52 | 27.00 ± 2.65 | 38.33 ± 2.52 |
| NaA1.5b | 480.0 ± 22.6∗∗ | |||
| 2AF 20b | 2280.0 ± 169.7∗∗ | 3300.0 ± 141.4∗∗ | ||
| PA 100b | 992.0 ± 11.3∗∗ | |||
+S9: with hepatic fraction S9; −S9: without hepatic fraction S9.
aNegative control, dimethyl sulfoxide (DMSO).
bPositive controls. NaA: sodium azide; 2AF: 2-aminofluorene; PA: pichrolonic acid.
**P < 0.01 (Student's t-test).
Figure 1Cytotoxic effects of X. Strumarium extract in CHO cells by the MTT assay. Cells were exposed for 24 h to different concentrations (6.25, 12.5, 25, 50, and 100 μg/mL) of the extract. Negative control: DMSO (1%). Each value represents the mean ± SE of three independent experiments. Statistically significant difference compared to negative control (∗P < 0.05, ANOVA and Dunnett's test).
Figure 2SCE assay analysis in CHO cells treated with crude extract of X. strumarium L. (2, 5 and 15 μg/mL). Cells were exposed for 3 h or 27 h to X. strumarium extracts. Cultures received BrdUrd at the final concentration of 1.5 μg/mL during the last 24 h of incubation. Negative control: DMSO (1%). Each value represents the mean ± SD of three independent experiments. Statistically significant difference compared to negative control (∗P < 0.05, ANOVA and Dunnett's test).
Evaluation of chromosomal aberrations and mitotic index in CHO cells treated with whole extract of Xanthium strumarium L.
| Concentration | Number of cells | Aberrant cellsa (%) | Mitotic index (%) | Chromatid | Chromosome | bExch. | Total |
|---|---|---|---|---|---|---|---|
| DMSO 1% | 150 | 1.33 | 74 | 0.66 | 0.66 | 1.33 | |
|
| |||||||
| 3 h + 15 h recovery | |||||||
| 10 | 150 | 1.33 | 77 | 0.66 | 0.66 | 1.33 | |
| 25 | 150 | 4.00∗ | 62 | 0.66 | 3.33 | 4.00 | |
| 45 | 150 | 8.66∗∗ | 32 | 2.00 | 7.33 | 9.33 | |
|
| |||||||
| 18 h continuous | |||||||
| 10 | 150 | 2.00 | 44 | 0.66 | 1.33 | 2.00 | |
| 25 | 150 | 4.00∗ | 53 | 2.66 | 2.66 | 5.33 | |
| 45 | 150 | NM | 2 | ||||
| Mit Cc | 100 | 23.00∗∗ | 21.00 | 12.00 | 33.00 | ||
|
| |||||||
| RXd | 100 | 38.00∗∗ | 2.00 | 48.00 | 16.00 | 66.00 | |
aExcluding gaps; NM: no mitoses; bchromosome and chromatid exchanges; cmitomycin C positive control (0.05 μg/mL); dRX: positive control (2 Gy); ∗P < 0.05; ∗∗P < 0.01 versus DMSO sample.
Figure 3Comet assay analysis in CHO cells treated with fluid extract of Xanthium strumarium L. CHO cells were treated for 3 h with different concentrations (5, 15, and 45 μg/mL) of the extract. Positive control: hydrogen peroxide (100 μM for 20 min) and negative control: DMSO (1%). Each value represents the mean ± SD of three independent experiments. Statistically significant difference compared to negative control (*P < 0.05 versus DMSO sample, a P < 0.05 versus control at Mann-Whitney U test).
Micronucleus test results in mice treated with whole extract of Xanthium strumarium L.
| Dose (mg/kg) | Female | Male | ||
|---|---|---|---|---|
| PCE/NCEa ± SD | MNPCE/2000b ± SD | PCE/NCEa ± SD | MNPCE/2000b ± SD | |
| 0 | 0.46 ± 1.32 | 0.18 ± 0.43 | 0.35 ± 1.39 | 0.20 ± 0.24 |
| 500 | 0.07 ± 1.57 | 0.03 ± 0.08 | 0.10 ± 1.70 | 0.03 ± 0.11 |
| 1000 | 0.28 ± 1.58 | 0.06 ± 0.08 | 0.16 ± 1.51 | 0.03 ± 0.07 |
| 2000 | 0.08 ± 1.46 | 0.03 ± 0.11 | 0.07 ± 1.46 | 0.03 ± 0.11 |
| Ethanolc | 0.05 ± 1.39 | 0.01 ± 0.08 | 0.32 ± 1.45 | 0.04 ± 0.08 |
| CPd | 0.06 ± 0.63∗∗ | 1.80 ± 7.62∗∗ | 0.07 ± 0.53∗∗ | 0.75 ± 5.38∗∗ |
aPCE/NCE: polychromatic (PCE) to normochromatic (NCE) erythrocyte ratio; bMNPCE/2000: frequency of micronucleated PCE; cNegative control: ethanol 60%; dPositive control: cyclophosphamide 20 mg/Kg. ∗∗P < 0.01 (Student's t-test).